乌帕替尼能治愈特应性皮炎吗？

No, but upadatinib can relieve the symptoms of atopic dermatitis (AD) to a certain extent, and the vast majority of patients can achieve almost complete remission or even complete remission of the skin lesions. The European Medicines Agency (EMA), the U.S. Food and Drug Administration (FDA), and the China National Medical Products Administration (NMPA) approved it in August 2021, January 2022, and February 2022 respectively for the treatment of refractory, moderate to severe AD children and adolescents (≥12 years old) and adult patients who have poor response to systemic treatments such as hormones or are not suitable for the above treatments.

About atopic dermatitis

Atopic dermatitis (AD) is an inflammatory skin disease with severe itching, easy relapse, and is often accompanied by other atopic diseases such as allergic rhinitis. The global incidence rate is increasing. BYLUND et al. reviewed the overall global prevalence of AD, which ranged from 1.7% to 32.8% in children and from 1.2% to 9.7% in adults. The prevalence, incidence, medical utilization, and cost of AD are high, which seriously affect the quality of life of patients and families. It is currently a global public health problem.

The effect of upadatinib in the treatment of atopic dermatitis

A 16-week randomized, placebo-controlled, double-blind phase IIb clinical trial (NCTO2925117) evaluated the efficacy and safety of upadatinib monotherapy for AD for 16 weeks. Its primary endpoint was the percentage improvement from baseline in patients' Eczema Area and Severity Index (EASI) at week 16. The mean values ​​(standard errors) of the primary efficacy endpoints were 39% (6.2%), 62% (6.1%), and 74% (6.1%) in the 7.5, 15.0, and 30.0 mg upadatinib groups, respectively, and 23% (6.4%) in the placebo group. In addition, in the 7.5, 15.0, and 30.0 mg upatinib trial groups, the proportions of patients who achieved EASI-100 (skin rash area and severity index were reduced by at least 100.0%) at 16 weeks were 2.4%, 9.5%, and 24.0%, respectively, which were significantly higher than those in the placebo group. The trial data of this study showed that 30 mg upatinib had the best therapeutic effect.

References

[1] He Shihuan, Liu Jingping. Research progress on upadatinib in the treatment of atopic dermatitis [J]. Modern Medicine and Health, 2022, 38(20): 3508-3511+3516.

Recommended related articles: